• PDF / 141,043 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 112 Downloads / 144 Views

DOWNLOAD

REPORT

---

1

Imatinib/nilotinib Muscle and liver toxicities: 2 case reports Two men developed intolerances to imatinib therapy for hypereosinophilic syndrome; one also developed hepatic toxicity under nilotinib [routes not stated]. A 30-year-old man began receiving imatinib 200mg once daily in January 2006. After 2 months, he developed grade 3 muscular toxicity. His imatinib dosage was reduced to 100mg once daily, then increased the following year to 150mg once daily. His muscular toxicity persisted, and in June 2008 he refused imatinib. Nilotinib was commenced at 400mg twice a day. Two months later his dosage was reduced to 400mg once daily after he developed grade 1 liver toxicity. At last follow-up, he had excellent tolerance on his maintenance dose of nilotinib 200mg once a day. A 71-year-old man received imatinib 400mg once daily, and developed grade 3 hepatic toxicity. His dosage was slowly reduced to 50mg once a day, then discontinued after 8 months of therapy. His liver function slowly improved. Tabouret E, et al. Low-dose Nilotinib can maintain complete molecular remissions in FIP1L1/PDGFRA-positive hypereosinophilic syndrome. Leukemia Research 35: 136, No. 1, Jan 2011. Available from: URL: http://dx.doi.org/10.1016/ 803048588 j.leukres.2010.08.004 - France

0114-9954/10/1336-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved

Reactions 29 Jan 2011 No. 1336